Publications

Detailed Information

Prospective pilot study on combined use of pulsed dye laser and 1% topical rapamycin for treatment of nonfacial cutaneous capillary malformation

Cited 16 time in Web of Science Cited 17 time in Scopus
Authors

Doh, Eun Jin; Ohn, Jungyoon; Kim, Min Ji; Kim, Young Gull; Cho, Soyun

Issue Date
2017
Publisher
Taylor & Francis
Citation
Journal of Dermatological Treatment, Vol.28 No.7, pp.672-677
Abstract
Background: The regeneration or revascularization of blood vessels after pulsed dye laser (PDL) treatment is one of the causes of treatment failures of cutaneous capillary malformations (CM). Recently, topical administration of rapamycin was introduced as a possible adjunctive therapeutic option to minimize postlaser revascularization in facial CM.Objectives: We evaluated the effect of combined use of 1% topical rapamycin with PDL compared to PDL alone in cutaneous CM of trunk or extremities and tried to identify the optimal duration of topical rapamycin application.Methods: Three adjacent areas of cutaneous CM that had never been treated before were selected in each patient and underwent the following regimens: (A) PDL+vehicle for 8weeks post-PDL; (B) PDL+topical rapamycin for 1-week post-PDL and (C) PDL+topical rapamycin for 8weeks post-PDL. Each test site was treated by PDL for two sessions with 8weeks interval.Results: Only one of six patients showed clinical improvement with combined rapamycin treatment. Overall, there was no statistically significant difference in erythema and blanching rate among PDL alone and combined rapamycin regimens.Conclusion: One percent topical rapamycin does not seem to be effective as a treatment modality for cutaneous CM of trunk or extremities.
ISSN
0954-6634
Language
English
URI
https://hdl.handle.net/10371/147830
DOI
https://doi.org/10.1080/09546634.2017.1306018
Files in This Item:
There are no files associated with this item.
Appears in Collections:

Altmetrics

Item View & Download Count

  • mendeley

Items in S-Space are protected by copyright, with all rights reserved, unless otherwise indicated.

Share